India’s fertility chain raised ₹350 crore after 40 years without outside money

In 1986, when Dr. S. Chandralekha started what would become Iswarya Fertility Center, IVF wasn't just expensive in India, it was largely out of reach, unfamiliar, and quietly stigmatised. Nearly forty years later, her organisation has just closed a Rs 350 crore growth round from OrbiMed Asia, one of the world's largest dedicated healthcare investors. What makes that headline unusual isn't the number. It's that this is the first time in Iswarya's four-decade history that it has taken any external funding at all.

Built slowly, entirely on its own terms

Most fertility chains that have scaled across India in the last decade did it with venture capital fuelling rapid, sometimes aggressive expansion. Iswarya took the opposite route. Founded in Chennai in 1986 by Dr. Chandralekha alongside co-founder Veluswamy, the organisation grew centre by centre, entirely self-funded, for close to forty years. Today, it operates more than 85 centres across eight states, making it the largest fertility care network in South India, and says it has helped more than 300,000 couples build families over that period.

Dr. Chandralekha, who remains founder and chief clinical officer, has been direct about the philosophy behind that slow-and-steady growth: every centre Iswarya has opened has been guided by the belief that clinical excellence and compassion must go hand in hand, not one prioritised over the other for the sake of faster expansion.

Why the timing of this round matters

India's fertility numbers explain why a healthcare investor like OrbiMed is paying close attention now. According to the government's Sample Registration System Statistical Report for 2024, India's total fertility rate has fallen to 1.9, below the replacement rate of 2.1 required for long-term population stability. At the same time, delayed parenthood, lifestyle-related fertility issues, and improved diagnosis rates mean more couples than ever are being identified as needing fertility treatment, even as IVF treatment penetration in India remains among the lowest globally. That gap between rising need and low access is precisely the opportunity Iswarya, and now OrbiMed, are betting on.

Iswarya's managing director, Dr. Arun Muthuvel, framed the company's next chapter around exactly that gap: deepening its presence in existing markets, entering underserved geographies that larger chains have overlooked, and continuing to raise clinical outcome standards rather than simply opening centres faster than competitors.

What OrbiMed is actually betting on

For OrbiMed, an investment firm that manages roughly $18 billion in assets globally and has historically focused on biopharmaceuticals, medical devices, and diagnostics, this marks a deliberate extension into fertility care specifically. In a joint statement, OrbiMed's Sunny Sharma and Arun Sadhanandham pointed to exactly what four decades of bootstrapped discipline had built: strong clinical outcomes, a trusted brand, and what they called a capital-efficient operating model, essentially, a business that had already proven it works before ever taking outside money to scale it faster.

The fresh capital will go toward opening new centres in underserved regions, strengthening clinical infrastructure, building out digital capabilities, and expanding Iswarya's embryology talent pipeline, the specialised skill base that's often the real bottleneck in scaling fertility care responsibly.

Why this story matters

Iswarya's funding round isn't really a story about a hot new startup catching investor attention. It's closer to the opposite: a healthcare institution that spent forty years proving its model worked without outside capital, patiently, one centre and one family at a time, before ever needing to ask for it. In an industry often driven by growth-at-all-costs thinking, Iswarya's path is a reminder that sometimes the businesses worth the biggest checks are the ones that took the longest to ask for one.